CSIMarket
 
Atea Pharmaceuticals Inc   (AVIR)
Other Ticker:  
 
 
Price: $4.0100 $0.16 4.156%
Day's High: $4.015 Week Perf: -0.5 %
Day's Low: $ 3.80 30 Day Perf: -0.25 %
Volume (M): 614 52 Wk High: $ 5.19
Volume (M$): $ 2,464 52 Wk Avg: $3.49
Open: $3.80 52 Wk Low: $2.77



 Market Capitalization (Millions $) 334
 Shares Outstanding (Millions) 83
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -131
 Cash Flow (TTM) (Millions $) -39
 Capital Exp. (TTM) (Millions $) 0

Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc, founded in 2014, is a biopharmaceutical company headquartered in Boston, Massachusetts, USA. The company is focused on discovering and developing novel antiviral therapeutics to treat infectious diseases. Their proprietary platform is based on the use of nucleotide prodrugs that target the viral RNA polymerase, a key enzyme essential for viral replication.

Atea Pharmaceuticals is particularly focused on developing antiviral therapies to combat RNA viruses like hepatitis C virus (HCV), respiratory syncytial virus (RSV), and most recently, the novel coronavirus (SARS CoV-2) responsible for COVID-19. The company has built a team of experienced scientists, biotech innovators, and clinical development experts with deep expertise in antiviral drug discovery and development.

Their lead drug candidate, AT-527, is being developed as an oral antiviral therapy for the treatment of influenza and COVID-19. In preclinical studies, AT-527 has demonstrated potent antiviral activity against a broad range of influenza strains and activity against SARS CoV-2 in vitro. The drug has received Fast Track designation from the US FDA for the treatment of COVID-19, and clinical trials are ongoing.

In addition to AT-527, Atea Pharmaceuticals has a pipeline of other antiviral candidates in preclinical development, including compounds for the treatment of RSV and HCV. The company has also established partnerships with leading academic institutions and biotech companies to collaborate on the development of antiviral therapies.

Atea Pharmaceuticals is backed by a group of leading venture capital firms, including Morningside Ventures, Cormorant Asset Management, and RA Capital Management. The company has raised over $500M in funding since its inception and has grown its team to more than 150 employees.

Overall, Atea Pharmaceuticals Inc is a rapidly growing biopharmaceutical company that is committed to developing innovative antiviral therapies to address unmet medical needs and improve patient outcomes.


   Company Address: 225 Franklin Street Boston 2110 MA
   Company Phone Number: 284-8891   Stock Exchange / Ticker: NASDAQ AVIR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Atea Pharmaceuticals Makes Striking Progress: 98% Success in Phase 2 Hepatitis C Study and Major Milestone in Phase 3 Trial for COVID-19

Published Mon, Jan 8 2024 9:05 PM UTC

Atea Pharmaceuticals, a biopharmaceutical company focused on discovering and developing antiviral therapeutics, recently announced positive initial data from a Phase 2 study for Hepatitis C Virus (HCV) and a significant enrollment milestone for their Phase 3 SUNRISE-3 trial for COVID-19. This groundbreaking study showcased a remarkable 98% sustained virologic response at Wee...

Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc. Releases Impressive Q3 2023 Results, Announced by AVIR

Investors in the Major Pharmaceutical Preparations sector are closely watching the performance of Atea Pharmaceuticals Inc as they interpret its third-quarter 2023 results. The company recently announced an operating shortfall of $-40.785 million for the period from July to September 30, 2023. Notably, Atea Pharmaceuticals Inc has not yet disclosed any revenue figures.
To gain further context, experts are comparing the current performance with that of the third quarter of 2022. During that period, the company reported an operating shortfall of $-16.281 million. It comes as no surprise that the evolving organization experienced a net loss of $-33.142 million, an increase from the $-8.066 million loss reported in the previous fiscal year, which ended on September 30, 2022.

Atea Pharmaceuticals Inc

AVIR's Major Pharmaceutical Preparations Market Shows Significant Growth in Q2 2023

Atea Pharmaceuticals Inc is a company that has recently caught the attention of investors due to its financial performance and potential in the pharmaceutical industry. While the company's revenue has not been predicted to undergo any significant modifications during the earnings cycle between April and June 2023, investors have observed a notable operating loss during this period.
During the mentioned time frame, Atea Pharmaceuticals Inc recorded an operating loss of $-35.235 million. Although this may raise concerns among investors, it is important to analyze the situation in the context of the company's overall performance. By comparing the operating loss of the second quarter of 2022, which amounted to $-32.295 million, we see that the losses have actually decreased to $-28.183 million in the second quarter of 2023. This improvement is a promising revelation that indicates the company is making progress on its path to becoming a standout leader in the industry.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com